Merck Joins Novo to Reassure FDA of Diabetes Drug Safety

Merck & Co., Novo Nordisk A/S and other makers of popular treatments for diabetes may be asked to collect more data on a potential cancer link even as they try to reassure U.S. regulators this week of the drugs’ safety.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.